Cargando…
The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine
BACKGROUND: Chloroquine, a quinolone antimalarial drug, is known to potentially inhibit pH-dependent viral replication of the SARS-CoV‑2 infection. Therefore, chloroquine is considered as a treatment option for coronavirus disease 2019 (COVID-19). Chloroquine is known for prolonging the QT interval,...
Autores principales: | Sinkeler, F. S., Berger, F. A., Muntinga, H. J., Jansen, M. M. P. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346846/ https://www.ncbi.nlm.nih.gov/pubmed/32648153 http://dx.doi.org/10.1007/s12471-020-01462-6 |
Ejemplares similares
-
QTc interval prolongation, COVID-19 and chloroquine
por: Wiwanitkit, V.
Publicado: (2020) -
Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals
por: Brüggemann, R.J., et al.
Publicado: (2021) -
Chloroquine-induced QTc prolongation in COVID-19 patients
por: van den Broek, M. P. H., et al.
Publicado: (2020) -
QTc Prolongation in COVID-19 Patients Using Chloroquine
por: Becker, Matthijs L., et al.
Publicado: (2021) -
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)